CRSP

#1107
CRISPR Therapeutics AG - Common Shares
56.1 8 USD
-0.35%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
56.18
56.18
Jahresspanne
35.48
78.48
Tagesänderung
-0.35%
Monatliche Änderung
+9.47%
6 month change
+7.42%
Jahresänderung
+52.25%
Vorheriger Schlusskurs
56.3 8
Open
56.1 8
Tief
56.1 8
High
56.1 8
Volumen
132
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 5.42 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry Biotechnologie
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-7.71
Preis-Umsatz-Verhältnis
1 062.57

CRISPR Therapeutics AG - Common Shares

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

Nachrichten